Loading organizations...
§ Private Profile · Paris, France
TISSIUM is a technology company.
TISSIUM develops biomorphic programmable polymers for tissue reconstruction, addressing a critical need in medical procedures. Its proprietary technology utilizes polymer building blocks that can be adjusted to match tissue-specific requirements, allowing them to conform to and integrate seamlessly with surrounding biological structures. The company’s flagship product, COAPTIUM® CONNECT, exemplifies this approach, offering an FDA-authorized system for atraumatic sutureless nerve coaptation.
The company was founded in 2013 by scientists Robert Langer and Jeffrey Karp, alongside Christophe Bancel, to tackle the persistent medical challenge of effectively reconstructing damaged tissue and restoring its natural function. Their founding insight centered on developing bio-inspired tissue adhesives, aiming for solutions that offer leak-proof seals on demand, even in complex physiological environments. This academic and entrepreneurial pedigree underscored the company's early scientific foundation.
TISSIUM designs solutions for various tissue types, targeting applications in both open surgery and minimally invasive procedures across therapeutic areas such as peripheral nerve, cardiovascular, and gastrointestinal systems. The company envisions creating the future of tissue reconstruction by continuing to develop innovative polymer-based products that provide precise, adaptable, and long-lasting repair, ultimately enhancing patient outcomes and clinical efficacy.
TISSIUM has raised $202.3M across 8 funding rounds.
TISSIUM has raised $202.3M in total across 8 funding rounds.
TISSIUM has raised $202.3M in total across 8 funding rounds.
TISSIUM's investors include Abingworth, Soffinova Partners, Cathay Capital, Credit Mutuel Innovation, ISALT, Merieux Equity Partners, Hongjie Hu, BNP Paribas Développement, Bpifrance, European Investment Fund, Karista, M&L Investments.
TISSIUM has raised $202.3M across 8 funding rounds. Most recently, it raised $54.0M Series D in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2023 | $54M Series D | — | Abingworth, Soffinova Partners, Cathay Capital, Credit Mutuel Innovation, Isalt, Merieux Equity Partners | Announced |
| Aug 1, 2021 | $59M Series C | Soffinova Partners, Hongjie HU | Abingworth | Announced |
| Nov 20, 2019 | $42.9M Series B | — | BNP Paribas Développement, Bpifrance, Credit Mutuel Innovation, European Investment Fund, Karista, M&L Investments, Omnes Capital, Sofinnova Partners, Valquest Partners | Announced |
| Jan 24, 2018 | $7.4M Venture Round | Marie Zwarg | — | Announced |
| Jun 30, 2016 | $1.5M Debt Financing | Bpifrance | — | Announced |
| Mar 1, 2016 | $25M Series A | Antoine Papiernik | Seroba Life Sciences, Chahra Louafi, Credit Mutuel Innovation, Karista, Omnes Capital | Announced |
| Jan 20, 2015 | $1.5M Venture Round | Bpifrance | — | Announced |
| Dec 1, 2013 | $11M Series A | Karine Lignel, Alexia Perouse | Karista, Paul Walker, Seroba Life Sciences | Announced |
TISSIUM is a clinical-stage medtech company developing proprietary biomorphic programmable polymers for atraumatic tissue reconstruction in surgery.[1][7] It builds a platform of fully biosynthetic, elastomeric products including sealants, adhesives, and 3D-printed implants, serving surgeons and patients in cardiovascular, nerve repair, hernia repair, and other procedures to solve persistent challenges in restoring damaged tissue function without sutures or tacks.[2][5][6] With one commercial product (COAPTIUM® CONNECT for sutureless nerve repair, first used commercially in the US in November 2025) and six in development across three verticals, TISSIUM shows strong growth momentum, including 3 CE Marks, 64 granted patents, FDA De Novo Grant, and expansion into manufacturing and global clinical studies.[1][2][6]
The company's integrated platform supports internal programs and partnerships, with offices in Paris, Boston, and a manufacturing site in Roncq, France.[1][3][6]
TISSIUM was founded in 2013 in Paris (initially as Gecko Biomedical) by CEO Christophe Bancel and co-founder Maria Pereira, PhD (now Chief Innovation Officer), leveraging breakthrough polymer research from MIT's Robert Langer and Brigham and Women's Hospital's Jeffrey M. Karp.[1][5][8] The idea emerged from recognizing the polymers' potential—discovered in their US labs—to revolutionize tissue reconstruction, a challenge dating back to early surgery.[1][3]
Early traction included a 2013 Science Translational Medicine publication, first ISO certification, vascular sealant clinical testing, and platform expansion to 3D printing.[1] Pivotal moments: GLP pre-clinical studies completed for nerve (COAPTIUM®) and hernia (ECLIPSIUM) products, nerve clinical study completion, FDA De Novo Grant for COAPTIUM® CONNECT, and pipeline growth to seven products.[1][6]
TISSIUM stands out through its proprietary technology and system-level approach:
TISSIUM rides the medtech trend toward biomaterials and minimally invasive, atraumatic surgery, addressing multi-billion-dollar markets in tissue repair amid rising procedure volumes from aging populations and complex interventions.[2][5] Timing aligns with advances in programmable materials and 3D bioprinting, enabling customizable solutions for unmet needs like high-pressure vascular sealing or peripheral nerve regeneration.[1][7]
Market forces favoring it include demand for sutureless alternatives reducing complications, global medtech partnerships (e.g., Sofinnova), and cross-border expansion (US/Europe/Asia).[2][6] It influences the ecosystem by pioneering biosynthetic polymers from academic IP, fostering co-developments, and setting standards for reconstructive tech in cardiovascular, GI, ENT, and neurosurgery.[1][5]
TISSIUM's momentum—marked by COAPTIUM® CONNECT's US launch—positions it for pipeline commercialization, starting with hernia and cardiovascular products, while expanding to ENT, fistulas, and neurosurgery via partnerships.[6] Trends like AI-driven customization, global regulatory harmonization, and biotech-medtech convergence will accelerate its growth, potentially capturing share in $10B+ repair markets.
Its influence may evolve from innovator to platform leader, enabling broader atraumatic procedures worldwide, building on MIT roots to redefine surgical reconstruction.[1][2] This cements TISSIUM's role in a new era of tissue repair, directly tackling surgery's core challenge.[7]